Halol in Gujarat is like any other obscure town, but for those watching the Indian pharma industry closely, it is a hotspot.About 40% of the US revenues of Sun Pharmaceutical Industries , India's most valuable pharmaceutical company, is linked to its Halol site. If things go as planned, the Halol site may be cleared within three months, say analysts.There's added cause for optimism from another important site, at Dadra, where Sun has been able to solve its quality issues quickly. Last April, the USFDA had found as many as 11 quality and procedural violations at the unit. Sun Pharma has been regarded as one of the most strategically managed pharmaceutical companies in India. Shanghvi must be hoping that slowly but surely, the outlook for his company is turning bright again.

Source: Economic Times February 26, 2018 05:01 UTC